<SEC-DOCUMENT>0001193125-25-305551.txt : 20251203
<SEC-HEADER>0001193125-25-305551.hdr.sgml : 20251203
<ACCEPTANCE-DATETIME>20251202181554
ACCESSION NUMBER:		0001193125-25-305551
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20251202
FILED AS OF DATE:		20251203
DATE AS OF CHANGE:		20251202

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		251544402

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000
		BUSINESS PHONE:		612 8315 7003

	MAIL ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d45983d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM&nbsp;6-K </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE&nbsp;13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date as December 02, 2025 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number&nbsp;001-35428 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#8217;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level&nbsp;32, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Indicate by check mark whether the registrant files or will file annual reports under cover of Form&nbsp;20-F or Form&nbsp;40-F. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form 40-F&#8194;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as permitted by Regulation&nbsp;S-T
Rule&nbsp;101(b)(1):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as permitted by
Regulation&nbsp;S-T Rule&nbsp;101(b)(7):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Indicate by check mark whether by furnishing the information contained in this
Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If &#8220;Yes&#8221; is marked, indicated below the file number assigned to the registrant in connection with Rule&nbsp;12g3-2(b): Not
applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="d45983dex991.htm">Immutep to Present New Data from AIPAC-003 Phase II at the 2025 San Antonio Breast Cancer Symposium
 </A></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: December 02, 2025 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d45983dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g45983g1202081127432.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="center"><B>Immutep to Present New Data from <FONT STYLE="white-space:nowrap">AIPAC-003</FONT> Phase II at </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="center"><B>the 2025 San Antonio Breast Cancer Symposium </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Arial; font-size:10pt">Immunotherapy-chemotherapy combination of eftilagimod alfa (efti) and paclitaxel led to strong objective response rates
and immune activation in heavily pretreated metastatic breast cancer patients </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Arial; font-size:10pt"><FONT STYLE="white-space:nowrap">AIPAC-003</FONT> has resulted in successful completion of FDA&#8217;s Project Optimus
requirements and selection of 30 mg as efti&#8217;s optimal biological dose </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify"><B>SYDNEY, AUSTRALIA &#8211;
December</B><B></B><B>&nbsp;2, 2025 &#8211;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#8220;Immutep&#8221; or &#8220;the Company&#8221;), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces new
data from the <FONT STYLE="white-space:nowrap">AIPAC-003</FONT> trial will be presented at the 2025 San Antonio Breast Cancer Symposium (SABCS) taking place in San Antonio, Texas, from December <FONT STYLE="white-space:nowrap">9-12,</FONT> 2025.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">The Phase II study randomised female participants (N=66) with HR+ and <FONT STYLE="white-space:nowrap">HER2-negative/HER2-low</FONT> metastatic
breast cancer (MBC) resistant to endocrine-based therapy (ET) including cyclin-dependent kinase 4/6 (CDK4/6) inhibitors or metastatic triple-negative breast cancer (mTNBC) not eligible for <FONT STYLE="white-space:nowrap">PD-(L)1-based</FONT>
therapy. Patients were randomised 1:1 to receive either 30 or 90 mg eftilagimod alfa (efti) in combination with paclitaxel to determine the optimal biological dose (OBD) consistent with the FDA&#8217;s Project Optimus initiative. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">Both efti dosing levels on top of weekly paclitaxel in heavily pretreated metastatic breast cancer patients, who received a median of three prior lines
of systemic therapy, led to strong objective response rates (ORR) and disease control rates (DCR) of 41.9% and 87.1% (30 mg efti) and 48.5% and 78.8% (90 mg efti), respectively, in the evaluable population (N=64). Time to onset of response (TTR) was
comparable at 2.0 months (30 mg) versus 1.9 months (90 mg). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">Additionally, both dosing levels elicited the desired pharmacodynamic (PD) response in
line with efti&#8217;s mechanism of action with substantial increases in immune activation biomarkers including absolute-lymphocyte count (ALC) and interferon-gamma <FONT STYLE="white-space:nowrap">(IFN-&#947;).</FONT> Data <FONT
STYLE="white-space:nowrap">cut-off</FONT> date for efficacy results was 15&nbsp;September 2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify"><B>Dr.</B><B></B><B>&nbsp;Nuhad Ibrahim, Professor,
Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center</B> noted, &#8220;Evaluating two biologically active doses allowed us to integrate clinical response data with meaningful
pharmacodynamic readouts. In keeping with Project Optimus principles, the study generated rigorous comparative data in heavily pretreated metastatic breast cancer patients showing consistent efficacy measures and immune-activation signals across
both arms, reinforcing efti&#8217;s novel mechanism of action and the clinical potential of this immunotherapy-chemo combination.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">Tolerability at 90 mg was suboptimal including dose-limiting toxicities (DLT) and a higher proportion of local injection site reactions (LISR). In line
with FDA guidance/advice and as previously reported on 13&nbsp;October 2025, 30 mg of efti administered subcutaneously has been defined as the OBD. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g45983g1202081127530.jpg" ALT="LOGO">
</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Arial; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"><B>Immutep Limited</B>, Level 32, Australia Square, 264 George Street, Sydney NSW 2000, Australia; ABN: 90 009 237 889</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify"><B>Marc Voigt, CEO of Immutep </B>said, &#8220;We are pleased to conclude this important phase of
efti&#8217;s clinical development and are fully committed to advancing this novel immunotherapy to address the needs of cancer patients globally, especially in light of our ongoing Phase III in
1<SUP STYLE="font-size:75%; vertical-align:top">st</SUP> line NSCLC. This study holds significant importance in satisfying FDA&#8217;s Project Optimus requirements and defining efti&#8217;s OBD across our entire oncology clinical pipeline and
potential future combinations with new therapeutic agents such as ADCs and bispecifics as well as for a potential future Biological Licence Application.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">The <FONT STYLE="white-space:nowrap">AIPAC-003</FONT> trial has resulted in the successful completion of the FDA&#8217;s Project Optimus requirements
and agreement on 30 mg as efti&#8217;s OBD carries strategic importance in ongoing and future clinical programs in oncology. This includes the global <FONT STYLE="white-space:nowrap">TACTI-004</FONT>
<FONT STYLE="white-space:nowrap">(KEYNOTE-F91)</FONT> Phase III trial evaluating efti in combination with MSD&#8217;s (Merck&nbsp;&amp; Co., Inc., Rahway, NJ, USA)
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab), and chemotherapy as first-line treatment for advanced or metastatic
<FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (1L NSCLC), regardless of <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression, which is now in the process of opening sites in the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Arial"><B>Details on the SABCS 2025 presentation are as follows: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify"><B>Title</B>: Optimal biological dose of eftilagimod alpha, a soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein, in metastatic breast cancer
patients receiving weekly paclitaxel in <FONT STYLE="white-space:nowrap">AIPAC-003</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify"><B>Presenter</B>: Dr.&nbsp;Nuhad Ibrahim, Professor,
Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial"><B>Presentation number</B>: <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PS1-09-16</FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial"><B>Abstract number</B>: 315 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial"><B>Date and time</B>: Wednesday, December 10<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> at <FONT STYLE="white-space:nowrap">12:30-2:30</FONT> p.m. CST </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">The poster presentation is available on the Posters&nbsp;&amp; Publications section of Immutep&#8217;s website. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Arial"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">Immutep is a late-stage biotechnology company
developing novel immunotherapies for cancer and autoimmune disease<I>.</I> The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation <FONT STYLE="white-space:nowrap">Gene-3</FONT><B> </B><FONT
STYLE="white-space:nowrap">(LAG-3),</FONT> and its diversified product portfolio harnesses <FONT STYLE="white-space:nowrap">LAG-3&#8217;s</FONT> ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise
to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit <U>www.immutep.com</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify"><I>KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> is a registered trademark of Merck Sharp&nbsp;&amp; Dohme LLC, a subsidiary of
Merck&nbsp;&amp; Co., Inc., Rahway, NJ, USA. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Arial"><B>Australian Investors/Media: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">Eleanor Pearson, Sodali&nbsp;&amp; Co. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial">+61 2 9066 4071;
<U>eleanor.pearson@sodali.com</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Arial"><B>U.S. Investors/Media: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Arial">Chris Basta,
VP, Investor Relations and Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial">+1 (631) 318 4000; <U>chris.basta@immutep.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">This announcement was authorised for release by the CEO of Immutep Limited. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g45983g1202081127530.jpg" ALT="LOGO">
</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Arial; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"><B>Immutep Limited</B>, Level 32, Australia Square, 264 George Street, Sydney NSW 2000, Australia; ABN: 90 009 237 889</TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g45983g1202081127432.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g45983g1202081127432.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ^ +,# 2(  A$! Q$!_\0
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M:W\5A/>P1W4W^KB9P&;/3CWJ[0%PHHHH **** "BBB@ HHHH **** "BBB@
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MH_AY]+U%[IIU?<A7 &.I'^%)/<TG"3E!I;%/QO\ ZBS^K?\ LM37W_(B1_\
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M3'X'%:7BWS7,^6:@Z=C;N5+_  4 49/V-#^3 U!\'94.@W\(8>8MSN*]P"H
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HTVTTBPBL;*+RK>+.Q-Q.,DD\GGJ35NDW=W*BK12"BBBD4%%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g45983g1202081127530.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g45983g1202081127530.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  @ !\# 2(  A$! Q$!_\0
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+-M104X3KSYI(_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
